US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
FDA rethinking block on compounding of Lilly's obesity drug
The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to investigate whether shortages of the drug, which is sold by Lilly as Mounjaro for diabetes and Zepbound for obesity, have actually been resolved, as reported earlier this month.
HealthDay on MSN1d
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for NowOn October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
Forty years after the Hatch-Waxman Act created a market for affordable generic versions of prescription medications, ...
The Food and Drug Administration (FDA) on Friday declared shortages of three intravenous drugs produced at a North Carolina ...
After securing FDA approval, they produce and sell these drugs to distributors ... would offer GPOs bonus payments from Medicare for taking steps to prevent drug shortages, such as signing ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
Drug shortages that happen when demand surges can ... as compounded drugs are not FDA-approved and could have inconsistent potency. The FDA has issued warnings about the risks of compounded ...
Hurricane Helene damaged one of the major NC-based manufacturing facilities of IV fluids. What’s being done to help hospitals ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback